Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Large Volume Increase – Should You Buy?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares saw unusually-strong trading volume on Wednesday. 1,247,992 shares changed hands during trading, an increase of 81% from the previous session’s volume of 688,695 shares. The stock last traded at $21.0190 and had previously closed at $22.42.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FMS. Sanford C. Bernstein upped their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Truist Financial set a $25.00 price target on Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday, August 5th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a report on Tuesday, July 28th. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Seven equities research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $23.67.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.9%

The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. The business’s 50-day moving average is $23.02 and its two-hundred day moving average is $22.91. The firm has a market cap of $11.21 billion, a P/E ratio of 10.82, a P/E/G ratio of 3.79 and a beta of 0.74.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.62 by $0.04. The firm had revenue of $5.55 billion for the quarter, compared to analysts’ expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. As a group, analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of FMS. Pzena Investment Management LLC grew its stake in Fresenius Medical Care AG & Co. KGaA by 2.0% in the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock valued at $339,592,000 after purchasing an additional 299,986 shares in the last quarter. Moran Wealth Management LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock valued at $7,846,000 after buying an additional 83,311 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% in the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock valued at $7,701,000 after buying an additional 46,428 shares during the last quarter. Royal Bank of Canada boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock valued at $4,893,000 after buying an additional 179,418 shares during the last quarter. Finally, Assetmark Inc. grew its stake in shares of Fresenius Medical Care AG & Co. KGaA by 190.7% in the first quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock valued at $2,985,000 after buying an additional 86,798 shares in the last quarter. 8.37% of the stock is owned by institutional investors and hedge funds.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.